May 31, 2017

Boehringer Ingelheim launches first Mycoplasma synoviae vaccine in Korea

 

Boehringer Ingelheim (BI) Korea has launched the first Mycoplasma synoviae vaccine in Korea, Vaxsafe MS, in Daejeon on May 11, 2017.

Despite the recent Korean HPAI outbreak, a total 132 stakeholders attended the seminar to get information on the new product from BI. The attendees consisted of dealers including poultry vets (33%), production companies (36%), poultry farm owners (9%), and others (23%) including researcher and other animal health companies.

Distinguished speakers included Dr. Chris Morrow of Bioproperties (Advantage by Vaxsafe MS), Prof. Inpil Mo of Chungbuk National University (MS outbreaks in Korea) and Myeongseob Kim of BI Korea (Usage of Vaxsafe MS).